- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| Di | Brookline Capital upgrades Intensity Therapeutics stock rating to Buy | 3 | Investing.com | ||
| Di | Intensity Therapeutics regains compliance with Nasdaq requirement | 2 | Seeking Alpha | ||
| Di | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement | 82 | PR Newswire | SHELTON, Conn., Aug. 12, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology... ► Artikel lesen | |
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | Intensity Therapeutics GAAP EPS of -$0.13 | 1 | Seeking Alpha | ||
| Do | Intensity Therapeutics Inc.: Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | 40 | PR Newswire | Over $11 million raised since the beginning of 2Q 2025
Cash runway extended into the second half of 2026
In the INVINCIBLE-4 Study, patients receiving INT230-6... ► Artikel lesen | |
| Do | INTENSITY THERAPEUTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 04.08. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 04.08. | Intensity Therapeutics raises $6.6M via at-the-market offering | 2 | Seeking Alpha | ||
| 18.07. | Intensity Therapeutics: Aktionäre bestätigen Direktor und Wirtschaftsprüfer | 2 | Investing.com Deutsch | ||
| 18.07. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.06. | Intensity Therapeutics: INT230-6 Achieves Complete Responses In Murine Models Of MPNST | 1 | RTTNews | ||
| 30.06. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST) | 102 | PR Newswire | SHELTON, Conn., June 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology... ► Artikel lesen | |
| 27.06. | INTENSITY THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.06. | Intensity Therapeutics shares plummet on proposed public offering | 3 | Seeking Alpha | ||
| 11.06. | Intensity Therapeutics kündigt öffentliches Angebot von Stammaktien an | 3 | Investing.com Deutsch | ||
| 11.06. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase ... | 292 | PR Newswire | SHELTON, Conn., June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the... ► Artikel lesen | |
| 06.06. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 14.05. | Intensity Therapeutics GAAP EPS of -$0.22 | 2 | Seeking Alpha |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 95,00 | -0,11 % | Novo Nordisk Aktie: Heftig! - Allianz, BioNTech, Heidelberger, Infineon und Rheinmetall im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| NOVAVAX | 7,200 | -0,35 % | Novavax, Inc.: Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights | Total revenue of $239 million in the second quarter of 2025
Received FDA BLA approval for Nuvaxovid, the only recombinant protein-based, non-mRNA COVID-19 vaccine... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 48,200 | -0,82 % | CRISPR Therapeutics - CRSP: Short Squeeze bei der Schweizer Biotech-Aktie? | Short Float bei 29.37% Seit Jahren keine Gewinne bei CRISPR Therapeutics (CRSP). Insider kauft trotzdem! JETZT Pullback-Setup! CRISPR Therapeutics (CRSP) - ISIN CH0334081137 Rückblick: Die Kombination... ► Artikel lesen | |
| EDITAS MEDICINE | 1,950 | -0,38 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2025 Results and Business Updates | Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program... ► Artikel lesen | |
| GINKGO BIOWORKS | 9,800 | -1,01 % | Ginkgo Bioworks Reports Second Quarter 2025 Financial Results | Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets
BOSTON, Aug. 7, 2025 /PRNewswire/ --... ► Artikel lesen | |
| NOVOCURE | 9,616 | -1,05 % | Novocure Reports Second Quarter 2025 Financial Results | Quarterly net revenues of $159 million, up 6% year-over-year, with 4,331 active patients on therapy as of June 30, 2025 Results from Phase 3 PANOVA-3 clinical trial presented at 2025 ASCO Annual... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,069 | +3,79 % | Adaptimmune Therapeutics PLC - 8-K, Current Report | ||
| ADVERUM BIOTECHNOLOGIES | 2,040 | 0,00 % | Adverum Biotechnologies GAAP EPS of -$2.34 misses by $0.09 | ||
| AVIDITY BIOSCIENCES | 46,230 | 0,00 % | Aktien New York: Erholungspfad wieder aufgenommen - Apple ziehen stark an | NEW YORK (dpa-AFX) - Die US-Börsen haben am Mittwoch nach dem etwas schwächeren Vortag wieder den Weg nach oben eingeschlagen. Für Bewegung sorgten positiv aufgenommene Nachrichten zu Apple sowie Unternehmensberichte.... ► Artikel lesen | |
| 180 LIFE SCIENCES | 10,270 | 0,00 % | Peter Thiel-Backed 180 Life Sciences Surged 228% On Ethereum Holdings, ETHZilla Rebrand; Rally Continues After Hours | ||
| BEAM THERAPEUTICS | 16,860 | 0,00 % | Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) | With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,410 | 0,00 % | RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down | ||
| HARMONY BIOSCIENCES | 35,470 | 0,00 % | Mizuho raises Harmony Biosciences stock price target to $50 on increased confidence | ||
| SUMMIT THERAPEUTICS | 25,680 | 0,00 % | Evercore ISI hebt Kursziel für Summit Therapeutics auf 34 US-Dollar an | ||
| JANUX THERAPEUTICS | 24,270 | 0,00 % | Janux Therapeutics, Inc. - 10-Q, Quarterly Report |
INTENSITY THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,290 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.